|
|
|||||||||
CA: A Cancer Journal for Clinicians, Vol 50, Issue 3 184-200, Copyright © 2000 by American Cancer Society
D. P. Winchester, J. M. Jeske and R. A. Goldschmidt
The widespread utilization of screening mammography has produced a shift in
the stage of breast cancer at diagnosis in the US: Currently, 12% to 15% of
newly diagnosed breast cancer cases annually are ductal carcinoma in-situ
(DCIS). The diagnosis is made, in at least 90% of patients, with
mammography. Only about 10% of patients will have a palpable mass. The
accurate characterization and visualization of calcifications typically
requires magnification of mammographic imaging. The morphology of the
calcifications is generally considered to be the most important factor in
differentiating benign from malignant formations. Round and uniform shapes
are more likely to be benign, while linear and heterogeneous morphologies
are associated with DCIS. Following a complete mammographic work-up, most
suspicious lesions are potential candidates for a stereotactic core needle
biopsy. Ten percent to 50% of patients initially diagnosed with atypical
ductal hyperplasia by needle biopsy have subsequently been surgically
diagnosed with cancer near the biopsy site. Due to this relatively high
incidence of co-existent carcinoma, a needle biopsy diagnosis of atypical
ductal hyperplasia necessitates subsequent surgical excision. The most
important change in our thinking about DCIS was from a monolithic view,
conceiving of DCIS as a single disease highly likely to invade if left
untreated, to the realization that DCIS represents a non-obligate precursor
with a variable risk of progression, depending on a combination of factors,
such as histology, lesion, size, and margin status. In discussing treatment
options, patients should understand that local recurrence following total
mastectomy is rare and that this is the procedure of choice for disease
that cannot be adequately encompassed with a breast-conserving approach. If
the patient and her surgeon are in agreement about proceeding with a
breast-conserving approach, there needs to be a clear understanding of the
incidence and implications of local recurrence. In all such discussions
with newly diagnosed patients, however, it is essential to emphasize the
excellent prognosis with this disease, irrespective of the surgical
approach.
ARTICLES
The diagnosis and management of ductal carcinoma in-situ of the breast
Northwestern University Medical School, Evanston, IL, USA.
This article has been cited by other articles:
![]() |
E A Rakha and I O Ellis An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens J. Clin. Pathol., December 1, 2007; 60(12): 1300 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
M F Dillon, C M Quinn, E W McDermott, A O'Doherty, N O'Higgins, and A D K Hill Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice. J. Clin. Pathol., July 1, 2006; 59(7): 740 - 743. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Fahy, R. J. Bold, P. D. Schneider, V. Khatri, and J. E. Goodnight Jr Cost-Benefit Analysis of Biopsy Methods for Suspicious Mammographic Lesions Arch Surg, September 1, 2001; 136(9): 990 - 995. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |